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Abstract
Background
Campylobacter jejuni is the most common bacterial cause of human infectious intestinal
disease.
Methods
We genome sequenced 601 human C. jejuni isolates, obtained from two large prospective
studies of infectious intestinal disease (IID1 [isolates from 1993–1996; n = 293] and IID2
[isolates from 2008–2009; n = 93]), the INTEGRATE project [isolates from 2016–2017; n =
52] and the ENIGMA project [isolates from 2017; n = 163].
Results
There was a significant increase in the prevalence of the T86I mutation conferring resis-
tance to fluoroquinolone between each of the three later studies (IID2, INTEGRATE and
ENIGMA) and IID1. Although the distribution of major multilocus sequence types (STs) was
similar between the studies, there were changes in both the abundance of minority STs
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associated with the T86I mutation, and the abundance of clones within single STs associ-
ated with the T86I mutation.
Discussion
Four population-based studies of community diarrhoea over a 25 year period revealed an
increase over time in the prevalence of the T86I amongst isolates of C. jejuni associated
with human gastrointestinal disease in the UK. Although associated with many STs,
much of the increase is due to the expansion of clones associated with the resistance
mutation.
Introduction
Worldwide, the zoonotic pathogen Campylobacter is the most common bacterial cause of
acute gastroenteritis, responsible for an estimated 500,000 infections per annum in the United
Kingdom (UK) alone [1], representing an economic burden in excess of £1 billion each year
[2]. Campylobacteriosis, characterised by bloody diarrhoea, cramping, abdominal pain and
fever, and sometimes nausea and vomiting, is typically self-limiting and lasts for about a week.
However, occasionally more serious infections can occur, either because the pathogen enters
the bloodstream, or it is associated with a peripheral nervous system disorder, Guillain-Barre´
Syndrome. The majority of cases of campylobacteriosis are caused by C. jejuni (approximately
90% [3]).
In the UK, two large scale prospective studies of infectious intestinal disease incidence and
aetiology (Infectious Intestinal Disease Studies 1 and 2 [IID1 (1993–1996) and IID2 (2008–
2009), respectively]) identified Campylobacter as the most common bacterial pathogen among
both a community cohort and cases presenting to healthcare [1, 4].
Although most people with Campylobacter infections recover without treatment, antibiotic
therapy using macrolides or fluoroquinolones is recommended for the treatment of severe
Campylobacter infections [5], and there are concerns about increasing resistance. The World
Health Organization recently included fluoroquinolone-resistant Campylobacter amongst the
high priority pathogens against which new antibiotics are needed [6]. Specific mutations in the
gyrA gene, most notably the C257T mutation (T86I in the protein sequence), have been associ-
ated strongly with resistance to fluoroquinolones such as ciprofloxacin [7–11].
Multilocus sequence typing (MLST), based on analysis of sequences from several house-
keeping genes, has emerged as the key molecular technique in the study of diversity amongst
Campylobacter populations and the relationships between species within the genus [12, 13].
Using MLST, several studies have reported the prevalence of specific clones (sequence types
[STs]) amongst C. jejuni isolates from diverse sources [14–17], demonstrating that whilst
some MLST clonal complexes, such as the ST-21 complex, are widespread, others, such as the
ST-61 complex, have a more restricted distribution. MLST has also been used to identify cor-
relations between the T86I mutation associated with ciprofloxacin resistance and specific
clonal groups of C. jejuni [18, 19]. By determining the prevalence of specific sequence types
amongst isolates from potential sources, and comparing with similar data from isolates associ-
ated with infections in humans, various studies have estimated the relative contributions of
particular sources to transmission to humans [16, 17, 20]. This genetic attribution approach
has confirmed that the majority of human infections are associated with retail chicken meat
[16, 17].
Use of genomics to compare C. jejuni from four human infectious disease study datasets
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More recently, whole genome sequencing (WGS) has emerged as an affordable alternative
to MLST, offering far greater resolution and opportunities to improve our understanding of
both the epidemiology and the fundamental biology of bacterial pathogens [21]. Since the first
Campylobacter genome sequence (of strain NCTC11168) was published in 2000 [22], other
studies involving relatively small numbers of isolates have been conducted, revealing extensive
within-species diversity [23, 24]. It has been demonstrated that WGS analysis can be used to
predict antibiotic resistance in C. jejuni [25].
The aim of this study was to use whole genome sequencing to compare UK human C. jejuni
isolates from collections representing different time periods [IID1 (1993–1996), IID2 (2008–
2009) and two more recent studies (INTEGRATE and ENIGMA; 2016–2017)].
Materials and methods
C. jejuni isolates
The C. jejuni isolates used in this study were obtained from collections generated by four dif-
ferent UK studies: IID1[4], IID2[1], INTEGRATE[26] and ENIGMA. IID1 (1993–1996) and
IID2 (2008–2009) were two large scale prospective studies of infectious intestinal disease inci-
dence and aetiology. In IID1 and IID2, bacteria were isolated from faecal samples obtained
from patients of all ages attending 70 and 88 General Practitioner Practices respectively, across
the UK. Stored isolates from the IID1 and IID2 studies were obtained from Public Health
England. The INTEGRATE project (http://www.integrateproject.org.uk) involved collection
of faecal samples from unselected cases of acute gastroenteritis of all ages presenting to pri-
mary care across the north west of England (population 7.2 million) during the period 2016–
2017. Campylobacter isolates were obtained using Campylobacter Blood Free CCDA selective
agar (E & O Laboratories Ltd.) and incubated for 48 h at 42˚C.
In the ENIGMA project (http://www.enigmaproject.org.uk), clinical isolates of Campylo-
bacter from under five year olds were collected over the period August 2016 –October 2017
(n = 195) from 17 participating hospital diagnostic microbiology laboratories in England, all
with appropriate ethical approval in place. At the receiving laboratory the cultures on charcoal
swabs were recultured on to mCCDA plates, and the plates incubated at 37˚C for 48 h under
microaerobic conditions. The presence or absence of Campylobacter colonies was determined
visually and confirmed by visible agglutination with Microscreen Campylobacter latex confir-
mation assay (product code M46, Microgen Bioproducts).
A total of 601 C. jejuni isolates comprising 293 from IID1, 93 from IID2, 52 from INTE-
GRATE and 163 from ENIGMA were included in the study.
Extraction of DNA from Campylobacter
For the majority of isolates, genomic DNA was extracted using a QIAamp kit (QIAGEN), fol-
lowing the manufacturer’s instructions. Bacteria from single colonies were cultured on Colum-
bia blood agar incubated at 37˚C in microaerobic conditions (CampyGen, Oxoid) for 48 h,
and one or a few uniform colonies were used to inoculate 10–15 ml of Mueller Hinton broth
(with Campylobacter growth supplement, Oxoid) in a tissue culture flask with a vented lid. Fol-
lowing incubation of the culture for 24 h with gentle shaking under microaerobic conditions
at 37˚C, cells were harvested by centrifugation (3000 x g for 10 min) and washed in 1 ml phos-
phate-buffered saline. After further centrifugation, the pellet was used for DNA extraction. For
a minority of isolates, DNA was extracted directly from cell suspensions of bacterial cultures
grown on solid media, using the Wizard Genomic DNA Purification Kit (Promega) and the
manufacturer’s protocol for Gram-negative bacteria.
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Library preparation for Illumina sequencing
Libraries were constructed using the TruSeq Nano DNA Sample Preparation Kit (Illumina),
and 200 ng of input material. The material was sheared using a Covaris S2 ultrasonicator fol-
lowing the 550 bp insert size protocol. Half (100 ng) of the sheared material was cleaned using
1.6x Sample Purification beads, and half volumes of all reagents were used throughout the pro-
tocol. Samples were prepared in a 96-well plate format and size-selected using the Sample Puri-
fication beads. Following eight cycles of amplification, the libraries were purified using Sample
Purification beads. Each library was quantified using a Qubit (Thermofisher) and the size dis-
tribution was assessed using the Agilent 2100 Bioanalyzer. The samples were then pooled and
the final library assessed using the Agilent 2100 Bioanalyzer and subsequently subjected to
quantitative PCR using the Illumina Library Quantification Kit from Kapa on a Roche Light
Cycler LC480II, according to manufacturer’s instructions.
Sequencing on the Illumina platform
Isolates from both the ENIGMA and INTEGRATE studies were sequenced by paired-end
sequencing (2 x 150 bp) on the Illumina HiSeq 4000 platform (v1 chemistry). IID1 and IID2
isolates were sequenced by paired-end sequencing (2 x 100 bp or 2 x 125 bp) on the Illumina
2000 or HiSeq 2500 platforms (v3 chemistry).
Bioinformatic analysis for Illumina-derived sequence data
Sequence-adaptor trimmed paired-end reads in FASTQ format were trimmed to remove low
quality bases using Sickle 1.210 (https://github.com/najoshi/sickle) with a minimum window
quality score of 25. Trimmed reads were then assembled into contigs using SPAdes [27]. Sam-
ples were filtered by assembly quality, completeness and purity. Samples with an assembly size
between 1.4–2.1 MB were retained. Assemblies were analysed with BUSCO [28] and excluded
from further analysis if the frequency of duplicated single-copy core orthologues exceeded 5%
or the estimated completeness was lower than 95%, to remove potentially mixed isolates, and
incomplete assemblies, respectively. Finally, sample reads were analysed with MetaPhlAn2
[29] and samples comprising over 5% of a species other than Campylobacter jejuni were
removed. Following this, 601 samples were carried forward for analysis along with three refer-
ence strains: C.jejuni NCTC11168, RM1221 and 81–176, all obtained from NCBI (GenBank
accession numbers: HE978252.1, CP000025.1 and CP000538.1 respectively). MLST types
(using the 7 loci scheme: aspA, glnA, gltA, glyA, pgm, tkt, uncA) were determined for each iso-
late by aligning known alleles (obtained from https://pubmlst.org/campylobacter/) against
assemblies using Bowtie2 [30] and selecting perfect hits. In cases where no perfect hit to an
allele was detected, a novel allele was recorded and submitted to pubMLST (https://pubmlst.
org/campylobacter/). Similarly, novel profiles were also recorded and submitted.
The pan-genome of all remaining samples was calculated using LS-BSR [31], and a core
genome was extracted and aligned using the LS-BSR tool extract_core_genome.py, based on
genes with a BLAST score ratio of 0.8 or higher being classified as present in the genome. This
yielded a core genome of 994 genes, 1,007,194 bp. A maximum likelihood phylogeny was
reconstructed based on the core genome sequences using RAxML[32] (model: GTRGAMMA,
100 bootstraps) and visualised with the Interactive Tree of Life tool (iTOL [33]). Richness,
Simpson’s diversity (reciprocal index and index of diversity) and equitability metrics were cal-
culated using Python, based on isolate counts for each sequence type in each study.
gyrA mutations were detected as follows. Protein sequences were predicted in each assem-
bly using Prodigal [34]. GyrA sequences were extracted by BLASTP [35] searches against the
NCTC11168 GyrA sequence and aligned with MAFFT [36]. Variant sites relative to
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NCTC11168 were detected using a custom Python script. A similar approach was used to iden-
tify mutations in the rplD and rplV genes. Distance matrices based on SNP differences and
gene/presence absence between strains were carried out using snp-dists (https://github.com/
tseemann/snp-dists).
Database submission
All genome sequence data generated have been deposited in the European Nucleotide Archive
(ENA) site (study numbers: PRJEB7116 for the IID1 and IID2 isolates; PRJEB32069 for the
ENIGMA isolates; PRJEB32068 for the INTEGRATE isolates). An additional figure, entitled
“Phylogenetic tree based on core gene SNP phylogeny” is accessible via the link: https://itol.
embl.de/tree/138253218159113541547474319.
Results
Comparison of MLST profiles between C. jejuni from IID1 and IID2
A summary of all the C. jejuni genome sequence data using the Illumina platform is shown in
S1 Table. A summary of extracted MLST data from all 601 genomes sequenced is shown in
Table 1 and S2 Table. The most common C. jejuni STs were amongst the most abundant in
each of the four studies (ST-21, ST-45, ST-257 and ST-48). For other STs, there were examples
of variations in prevalence between the studies (Table 1). Some STs (eg. ST-5136, ST-6461)
were present only in the later studies (INTEGRATE and ENIGMA). In the ST-21 clonal com-
plex, there were a number of sequence types found only or mostly in the IID1 study: ST-47 (8
isolates), ST-104 (8 isolates), ST-262 (5 isolates) and ST-520 (4 isolates) (Table 1). However, it
is worth noting that using SNP phylogeny, these different STs within the ST-21 clonal complex
do not cluster together (Phylogenetic tree based on core gene SNP phylogeny, see Data Avail-
ability statement). In all, 23 novel MLSTs were submitted to the pubMLST.org database (ST-
7628 to ST-7633; ST-7635-ST-7642; ST-9576 to ST-9580; ST-9582; ST-9583 and ST-9585).
SNP phylogeny based on the C. jejuni core genome
We constructed a maximum likelihood phylogenetic tree for C. jejuni based on a 1,007,194 bp
core genome, comprising 994 genes (and 125,298 variable bases) and including the four study
datasets alongside three reference strains, C. jejuni NCTC11168, RM1221 and 81–176 (Phylo-
genetic tree based on core gene SNP phylogeny, see Data Availability statement). The tree con-
firms both (i) that the IID1, IID2, INTEGRATE and ENIGMA isolates are widely distributed
amongst the broader population and (ii) that there are small clusters of closely-related isolates
specific to individual studies (ie. containing isolates only from the ENIGMA study).
Comparison of diversity between the studies
We isolates compared the four studies on the basis of ST distributions to determine measures
of richness, Simpson’s Diversity Index and evenness. In terms of diversity, the four groups
were similar, but the IID1 isolate group was more uneven than the others (S3 Table).
Variations in prevalence of the T86I mutation
We observed a significant increase (p< 0.001; Fisher’s exact test) in the prevalence of the T86I
mutation between each of the three later studies (IID2, INTEGRATE and ENIGMA) and IID1
(Table 2). Increased prevalence was also observed when comparing either INTEGRATE or
ENIGMA data with IID2 data (Table 2).
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Table 1. Distribution of multilocus sequence types (STs) amongst isolates from the four studies.
ST IID1 IID2 Integrate Enigma TOTAL
(n = 292) (n = 93) (n = 52) (n = 162) (n = 599)
21 24 (0) 7 (1) 4 (1) 16 (7) 51 (9)
257 29 (0) 6 (0) 1 (0) 10 (2) 46 (2)
45 25 (0) 3 (0) 4 (0) 11 (0) 43 (0)
48 14 (1) 6 (0) 2 (0) 11 (1) 33 (2)
53 18 (0) 4 (0) 0 6 (0) 28 (0)
50 12 (1) 1 (0) 6 (2) 9 (1) 28 (4)
61 9 (0) 2 (0) 1 (0) 4 (0) 16 (0)
42 7 (0) 3 (0) 0 5 (0) 15 (0)
22 7 (0) 2 (0) 2 (0) 2 (0) 13 (0)
137 6 (0) 3 (0) 0 4 (0) 13 (0)
51 3 (0) 3 (1) 2 (0) 4 (1) 12 (2)
19 5 (1) 5 (1) 1 (0) 1 (1) 12 (3)
5136 0 0 1 (1) 8 (8) 9 (9)
104 8 (1) 0 1 (1) 0 9 (2)
52 5 (0) 2 (0) 0 1 (0) 8 (0)
47 8 (0) 0 0 0 8 (0)
464 0 2 (2) 1 (1) 5 (5) 8 (8)
206 5 (0) 1 (0) 1 (0) 1 (1) 8 (1)
354 1 (0) 2 (2) 2 (2) 2 (2) 7 (6)
49 7 (0) 0 0 0 7 (0)
267 3 (0) 0 0 4 (0) 7 (0)
227 3 (2) 0 0 4 (0) 7 (2)
6461 0 0 0 6 (6) 6 (6)
572 0 4 (4) 2 (2) 0 6 (6)
475 4 (0) 1 (0) 0 1 (0) 6 (0)
44 4 (0) 0 2 (2) 0 6 (2)
433 5 (2) 1 (0) 0 0 6 (2)
324 6 (0) 0 0 0 6 (0)
583 3 (0) 1 (0) 0 1 (0) 5 (0)
5 0 1 (0) 2 (2) 2 (2) 5 (4)
400 0 2 (0) 1 (1) 2 (2) 5 (3)
262 5 (0) 0 0 0 5 (0)
883 0 1 (1) 0 3 (2) 4 (3)
658 1 (1) 0 2 (0) 1 (0) 4 (1)
520 4 (0) 0 0 0 4 (0)
403 0 0 0 4 (1) 4 (1)
353 4 (0) 0 0 0 4 (0)
2254 0 0 1 (0) 3 (3) 4 (4)
205 4 (0) 0 0 0 4 (0)
132 2 (0) 0 0 2 (0) 4 (0)
122 0 0 0 4 (0) 4 (0)
singletons 51 (6) 30 (6) 13 (4) 25 (10) 119 (26)
STs are listed in descending order of abundance. The number of isolates containing the T86I mutation is indicated in parentheses. Only STs occurring at least four times
are identified in the table. Where STs occurred only once in the dataset, they are referred to as singletons. For two isolates, it was not possible to assign as ST because of
incomplete profiles.
https://doi.org/10.1371/journal.pone.0227535.t001
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The T86I mutation was present in 18% of C. jejuni isolates, but was associated with many
different STs (Table 1; S2 Table). Of the 109 isolates carrying the T86I mutation, 56 (52%)
were from nine STs (ST-5136, ST-21, ST-464, ST-6461, ST-354, ST-572, ST-2254, ST-5 and
ST-50). Of these, ST-5136, ST-464, ST-6461, ST-572, and ST-2254 are examples of STs with
only resistant isolates. None of these STs was present amongst the IID1 collection, and only
ST-464 and ST-572 were represented in the IID2 collection.
Though present as one of the most abundant STs in all collections, there was evidence for
an increase in carriage of the T86I mutation amongst ST-21 isolates, from 0/24 in IID1to 8/20
in INTEGRATE and ENIGMA combined (p = 0.0007, Fisher’s exact test; Table 1). In order to
investigate this further, we constructed a phylogenetic tree based on SNPs within the core
genomes of only the ST-21 isolates obtained from the four studies (Fig 1). This identified a
cluster including six ST-21 isolates from the ENIGMA study (ES00017, ES00132, ES00163,
ES00190, ES00051 and ES00112) associated with carriage of the T86I mutation, suggesting
expansion of a clone from within the ST-21 C. jejuni population. Pairwise comparisons were
used to generate distance matrices based on variations in SNPs and the presence/absence of
genes (Fig 2). This indicated SNP variations in the range 0–178 and gene presence / absence
variations in the range 44–170. There were no core SNP differences between isolates ES00132
and ES00163, but they differed by 55 genes (Fig 2).
There was evidence for the expansion of T86I-associated clones for ST-5136, ST-6461, ST-
464 and ST-572, each of which were not detected in IID1 but were present in later studies
(Table 1). There were also a large number (n = 26) of singletons or rarer STs with the T86I
mutation. However, it is also worth noting that there were abundant STs, such as ST-45, ST-53,
ST-61, ST-42, ST-22 and ST-137 that were never associated with the T86I mutation (Table 1).
Mutations in genes associated with macrolide resistance
In humans, the antibiotics most commonly used to treat Campylobacter infections are macro-
lides such as erythromycin. Mutations in ribosomal proteins L4 and L22 have been associated
with resistance to erythromycin in Campylobacter [37]. We identified mutations in the genes
encoding these proteins (rplD and rplV) and compared prevalence between the four groups.
The only difference reaching statistical significance was an increase in prevalence of an A103V
mutation in rplV (encoding L22), rising from 7.6% in IID1 to 19.6% in ENIGMA (p = 0.034).
A103V mutations in L22 have been reported previously in erythromycin-resistant Campylo-
bacter isolates, though the mutation can also occur in susceptible isolates [38, 39]. Mutations
in the 23S rRNA gene (position 2074 or 2075) have also been implicated in resistance to eryth-
romycin [38]. In our collection, only one isolate (H083720456) harboured such a mutation
(A2075G variant).
Discussion
Although not associated with high mortality, infections with Campylobacter spp. have high
prevalence in the community and can cause severe infections with few treatment options.
Table 2. Prevalence of the gyrA T86I mutation.
Source Present Absent Comparison p values (Fisher’s exact)
IID1 IID2 INTEGRATE ENIGMA
IID1 16 277 - 0.0002 <0.0001 <0.0001
IID2 18 75 - - 0.0176 0.0148
INTEGRATE 20 32 - - - 0.6165
ENIGMA 55 108 - - - -
https://doi.org/10.1371/journal.pone.0227535.t002
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Hence, fluoroquinolone-resistant Campylobacter spp. have been identified amongst the high
priority pathogens in the context of tackling antimicrobial resistance [6]. Using four different
collections of community-based human isolates we were able to examine trends over a 25-year
period and highlight differences in both the diversity of the C. jejuni population, and the car-
riage of a key fluoroquinolone-resistance mutation. The laboratory methods for primary diag-
nosis of Campylobacter spp. were consistent between the studies and so this should not have
biased the results. Only the ENIGMA collection was restricted by age but this is compensated
for by the fact that this group of strains overlapped with the INTEGRATE isolates, which were
derived from cases of all ages. This suggests that the increase in prevalence of fluoroquinolone
resistance witnessed in this study is real and not a result of sampling artefact. Antibiotic treat-
ment is not advocated at any age for uncomplicated campylobacteriosis. However, we were
unable to account for prescribing practice in this study. We have only limited access to data
about foreign travel, but only one of the isolates carrying the T86I mutation from the INTE-
GRATE study was associated with foreign travel, suggesting that this was not a major source of
C. jejuni containing this mutation.
Fig 1. Phylogenetic tree of C. jejuni ST-21 isolates (n = 51) carrying the T86I mutation. (A) Inner ring identifies the study and outer ring identifies
isolates carrying the GyrA T86I mutation. (B) Close up of a cluster of isolates mostly from the ENIGMA study. The tree is based on core genome SNP
differences. Within this sub-set of isolates, there were 12,265 variant nucleotides.
https://doi.org/10.1371/journal.pone.0227535.g001
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The MLST database (www.mlst.net) [40] currently contains >31,000 Campylobacter sub-
missions. Broadly speaking, the most common clonal complexes found amongst the C. jejuni
strains in this study reflect their abundance amongst the wider Campylobacter population. We
observed that the distributions of the major STs remained similar over time, but there were
changes in the prevalence of less abundant STs. In this study we further highlight the limita-
tions of the use of MLST clonal complexes when studying Campylobacter populations. We
found examples of a number of clonal complexes where isolates of different STs failed to
Fig 2. Comparative analysis of the genomes of ST-21 ENIGMA study isolates carrying the T86I mutation. The
figure shows (a) the number of SNP differences and (b) the number of genes that differ in terms of presence/absence
between the isolates. The reference strain NCTC11168 was included for comparison.
https://doi.org/10.1371/journal.pone.0227535.g002
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cluster together using core genome SNP phylogeny, a much higher resolution approach than
MLST. Examples include clonal complexes ST-21, ST-48, ST-206 and ST-257 (Phylogenetic
tree based on core gene SNP phylogeny, see Data Availability statement). In contrast, isolates
of identical MLST do mostly cluster together, suggesting that analyses based on individual
MLSTs may be much more robust than those based on clonal complex data. This must be
borne in mind when comparing with previous studies.
Fluoroquinolone resistance amongst human and farm animal isolates of C. jejuni has been
reported extensively [10, 41]. Previous studies have reported correlation between ciprofloxacin
resistance (and the T86I mutation) and specific clonal groups of C. jejuni [10, 18, 19, 42, 43].
In a six year study of 3300 human C. jejuni isolates in Oxfordshire, UK, nine clonal complexes
were significantly associated with ciprofloxacin sensitivity (ST- 22, ST-45, ST-48, ST-61, ST-
257, ST-283, ST-403, ST-658, ST-677) and seven clonal complexes were significantly associated
with ciprofloxacin resistance (ST-49, ST-206, ST-354, ST-446, ST-460, ST-464, ST-607) [44].
Likewise, in a survey of isolates from chicken meat, the ST-21 clonal complex was associated
with resistance but the ST-45 clonal complex was associated with susceptibility to ciprofloxacin
[10]. In agreement with these previous observations, in our study the T86I mutation was never
identified in isolates from ST-45, ST-22, ST-61 but was associated with isolates from ST-354
and ST-572 (from the ST-206 clonal complex). Notably, by core genome SNP phylogeny, the
ST-572 isolates do not cluster well with other members of the ST-206 clonal complex (includ-
ing ST-227 and ST-206 itself). This further highlights the limitations with considering changes
in terms of clonal complexes.
It has been suggested that the non-random association of MLST genotypes with resistance
phenotypes is indicative of clonal expansion of resistance-associated lineages, possibly driven
by the poultry industry [45]. We identified a number of STs contributing to the increased prev-
alence of the T86I mutation (ST-5136, ST-6461, ST-464). A previous study in Scotland, analys-
ing isolates associated with human campylobacteriosis and poultry from 1990–2012, reported
ST-5136 as a new strain emerging in the 2007–2011 period and associated with humans and
chickens [46]. The isolates (>50) of ST-6461 reported in the pubMLST database were mostly
from human stools in the UK and were all submitted post 2012. ST-464 was first reported in a
longitudinal study of clinical samples in Oxford, UK between 2003 and 2009, increasing over
that time period and associated with ciprofloxacin resistance [47].
Our data indicating increased prevalence of resistance-associated STs suggest that the main
cause for the overall increased prevalence of the T86I is clonal expansion. One potential driver
of this is the use of fluoroquinolones in farm animals. In the UK, fluoroquinolones have been
authorised for use in poultry since 1993. There has however been much pressure on all live-
stock sectors to reduce antimicrobial use, and there have been specific calls to ban fluoroquin-
olone use completely in livestock production. However, although in the USA fluoroquinolones
have been banned for use in poultry since 2005 and extra-label use is illegal, a similar rise in
fluoroquinolone resistance has been observed amongst human clinical isolates, from 16.3% in
2000 to 25.3% in 2015 (https://wwwn.cdc.gov/narmsnow/). In 2012, the British Poultry Coun-
cil (BPC), which represents 90% of the UK poultry industry committed to only using fluoro-
quinolones as last resort drugs, and to stop prophylactic use in day old chickens by 2016.
Hence, fluoroquinolones have accounted for only a very small proportion of antibiotic sales
(<1%) in the UK in poultry in recent years, and use has been falling. Data submitted to the
Veterinary Medicines Directorate from the BPC showed a reduction of 52% in fluoroquino-
lone use in the poultry sector between 2014 and 2015 alone [48], with a further reduction in
2016 [49]. The most recent voluntary reporting of use data by BPC members has allowed the
contribution of use within the poultry sector to be more accurately determined [50]. However,
it is worth noting that some products are authorised for specific diseases, therefore veterinary
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surgeons must follow the legal framework of the cascade, which can conflict with good antimi-
crobial stewardship, where there is susceptibility to other first line drugs but they are not
authorised for treatment of the disease.
If antibiotic usage is not the only driver for the expansion of lineages associated with the
T86I GyrA mutation, one alternative explanation could be that the mutation confers a fitness
advantage. It has been suggested that differences in the fitness costs contribute to the relatively
low prevalence of macrolide resistance in Campylobacter spp., compared to fluoroquinolone
resistance [11]. The T86I mutation hasbeen shown to reduce supercoiling GyrA activity [51]
but the link between this change in the activity of the protein and the fitness of the bacteria in
vivo is not clear. Enhanced fitness in the chicken host has been demonstrated for a fluoroquin-
olone resistant T86I mutant (C257T) in the absence of antibiotic selection [51, 52]. In addition,
surveillance studies have shown that levels of fluoroquinolone resistance persist in poultry
even after discontinued use of the antibiotics [53]. It has been demonstrated that resistance
can emerge rapidly in poultry flocks [54]. It may be that once emerged, reductions in fluoro-
quinolone use would not be sufficient to cause a reduction in prevalence. In our study, we
have observed an increased prevalence, suggesting that lineages associated with the mutation
may have an advantage regardless of antibiotic use. However, it is also possible that the muta-
tion, whilst not conferring a selective advantage, does not carry a fitness cost in a non-antibi-
otic environment, and hence can become fixed in the population.
Conclusions
In conclusion, four population-based studies of community diarrhoea over a 25 year period
afforded a unique opportunity to examine the prevalence of the T86I amongst isolates of
C. jejuni associated with gastrointestinal disease in the UK, which has increased significantly
over time despite the removal of selective pressure. Although associated with many STs, much
of the increase is due to the expansion of clones associated with the resistance mutation.
Supporting information
S1 Table. A summary of the C. jejuni WGS data generated and the extracted MLST profiles
(for all four studies).
(XLSX)
S2 Table. A summary of all isolate MLST types and the numbers of isolates carrying the
T86I mutation. On the “Concise” spreadsheet, yes refers to presence of the T86I mutation and
no refers to absence. The “Full” spreadsheet lists total numbers in each of the STs for each of
the four studies.
(XLSX)
S3 Table. Comparison of diversity between the four studies.
(XLSX)
Acknowledgments
The following people have all contributed to this project: Winifred Dove and Malgozarta
Wnek (bacterial culture, DNA extractions); Margaret Hughes, Pia Koldkjaer (sample Quality
Control); Anita Lucaci (Illumina Sequencing). We would like to thank Judith Richardson
(Public Health England) for processing the IID1 and IID2 strains, Lorna Wilson, Viki Owen
and Ashley McEwan for processing INTEGRATE samples and diagnostic laboratories across
England for providing Campylobacter isolates for the ENIGMA study.
Use of genomics to compare C. jejuni from four human infectious disease study datasets
PLOS ONE | https://doi.org/10.1371/journal.pone.0227535 January 30, 2020 11 / 15
The genotyping of IID1 and IID2 Study Campylobacter isolates was funded by the Food
Standards Agency, UK (FSA Project FS101072). The stored isolates were obtained with the
assistance of Judith Richardson, Gastrointestinal Bacteria Reference Unit, Public Health
England. ENIGMA was funded by the Medical Research Council, Natural Environment
Research Council, Economic and Social Research Council, Biotechnology and Biosciences
Research Council and Food Standards Agency through the Environmental and Social Ecology
of Human Infectious Diseases Initiative (ESEI) Project no. G1100799/1. INTEGRATE was
funded by the Wellcome Trust and Department of Health through the Health Innovation
Challenge Fund (HICF) Grant Reference: HICF-T5-354. SJOB and FJB are affiliated to the
National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in
Gastrointestinal Infections at University of Liverpool in partnership with Public Health
England (PHE), in collaboration with University of East Anglia, University of Oxford and the
Quadram Institute. SJOB and FJB are based at the University of Liverpool. The views expressed
are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of
Health or Public Health England.
Author Contributions
Conceptualization: Roy Chaudhuri, Nicola J. Williams, Ken Forbes, Norval J. Strachan, Caro-
line E. Corless, Tom J. Humphrey, Frederick J. Bolton, Sarah J. O’Brien, Neil Hall, Chris-
tiane Hertz-Fowler, Craig Winstanley.
Formal analysis: Sam Haldenby, Jane Pulman, Ian N. Winstanley, Craig Winstanley.
Funding acquisition: Roy Chaudhuri, Nicola J. Williams, Ken Forbes, Norval J. Strachan,
Tom J. Humphrey, Frederick J. Bolton, Sarah J. O’Brien, Neil Hall, Christiane Hertz-
Fowler, Craig Winstanley.
Investigation: Sam Haldenby, Christina Bronowski, Charlotte Nelson, John Kenny, Carmen
Martinez-Rodriguez.
Methodology: Sam Haldenby.
Project administration: Sarah J. O’Brien, Craig Winstanley.
Resources: Craig Winstanley.
Supervision: Sarah J. O’Brien, Craig Winstanley.
Writing – original draft: Craig Winstanley.
Writing – review & editing: Roy Chaudhuri, Nicola J. Williams, Ken Forbes, Norval J. Stra-
chan, Caroline E. Corless, Tom J. Humphrey, Frederick J. Bolton, Sarah J. O’Brien, Neil
Hall, Christiane Hertz-Fowler, Craig Winstanley.
References
1. Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, et al. Longitudinal study of infec-
tious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general
practice. Gut. 2012; 61(1):69–77. https://doi.org/10.1136/gut.2011.238386 PMID: 21708822.
2. Humphrey T, O’Brien S, Madsen M. Campylobacters as zoonotic pathogens: a food production per-
spective. IntJFood Microbiol. 2007; 117(3):237–57.
3. Facciola A, Riso R, Avventuroso E, Visalli G, Delia SA, Lagana P. Campylobacter: from microbiology to
prevention. J Prev Med Hyg. 2017; 58(2):E79–E92. PMID: 28900347.
4. Wheeler JG, Sethi D, Cowden JM, Wall PG, Rodrigues LC, Tompkins DS, et al. Study of infectious
intestinal disease in England: rates in the community, presenting to general practice, and reported to
Use of genomics to compare C. jejuni from four human infectious disease study datasets
PLOS ONE | https://doi.org/10.1371/journal.pone.0227535 January 30, 2020 12 / 15
national surveillance. The Infectious Intestinal Disease Study Executive. Bmj. 1999; 318(7190):1046–
50. Epub 1999/04/16. https://doi.org/10.1136/bmj.318.7190.1046 PMID: 10205103.
5. NICE. National Institute for Health and Care Excellence, Gastroenteritis:Summary. https://
cksniceorguk/gastroenteritis#!topicsummary. 2017.
6. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research,
and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculo-
sis. Lancet Infect Dis. 2018; 18(3):318–27. https://doi.org/10.1016/S1473-3099(17)30753-3 PMID:
29276051.
7. Ragimbeau C, Colin S, Devaux A, Decruyenaere F, Cauchie HM, Losch S, et al. Investigating the host
specificity of Campylobacter jejuni and Campylobacter coli by sequencing gyrase subunit A. BMC
Microbiol. 2014; 14:205. https://doi.org/10.1186/s12866-014-0205-7 PMID: 25163418.
8. Jesse TW, Englen MD, Pittenger-Alley LG, Fedorka-Cray PJ. Two distinct mutations in gyrA lead to cip-
rofloxacin and nalidixic acid resistance in Campylobacter coli and Campylobacter jejuni isolated from
chickens and beef cattle. J Appl Microbiol. 2006; 100(4):682–8. https://doi.org/10.1111/j.1365-2672.
2005.02796.x PMID: 16553723.
9. Hanninen ML, Hannula M. Spontaneous mutation frequency and emergence of ciprofloxacin resistance
in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. 2007; 60(6):1251–7. https://
doi.org/10.1093/jac/dkm345 PMID: 17911389.
10. Habib I, Miller WG, Uyttendaele M, Houf K, De Zutter L. Clonal population structure and antimicrobial
resistance of Campylobacter jejuni in chicken meat from Belgium. Appl Environ Microbiol. 2009;
75(13):4264–72. https://doi.org/10.1128/AEM.00168-09 PMID: 19411429.
11. Luangtongkum T, Jeon B, Han J, Plummer P, Logue CM, Zhang Q. Antibiotic resistance in Campylo-
bacter: emergence, transmission and persistence. Future Microbiol. 2009; 4(2):189–200. https://doi.
org/10.2217/17460913.4.2.189 PMID: 19257846.
12. Dingle KE, McCarthy ND, Cody AJ, Peto TE, Maiden MC. Extended sequence typing of Campylobacter
spp., United Kingdom. EmergInfectDis. 2008; 14(10):1620–2.
13. Miller WG, On SLW, Wang G, Fontanoz S, Lastovica AJ, Mandrell RE. Extended multilocus sequence
typing system for Campylobacter coli, C. lari, C. upsaliensis, and C. helveticus. J Clin Microbiol. 2005;
43(5):2315–29. https://doi.org/10.1128/JCM.43.5.2315-2329.2005 PMID: 15872261.
14. McCarthy ND, Colles FM, Dingle KE, Bagnall MC, Manning G, Maiden MC, et al. Host-associated
genetic import in Campylobacter jejuni. EmergInfectDis. 2007; 13(2):267–72.
15. French N, Barrigas M, Brown P, Ribiero P, Williams N, Leatherbarrow H, et al. Spatial epidemiology
and natural population structure of Campylobacter jejuni colonizing a farmland ecosystem. EnvironMi-
crobiol. 2005; 7(8):1116–26.
16. Wilson DJ, Gabriel E, Leatherbarrow AJ, Cheesbrough J, Gee S, Bolton E, et al. Tracing the source of
campylobacteriosis. PLoSGenet. 2008; 4(9):e1000203.
17. Sheppard SK, Dallas JF, Strachan NJ, MacRae M, McCarthy ND, Wilson DJ, et al. Campylobacter gen-
otyping to determine the source of human infection. ClinInfectDis. 2009; 48(8):1072–8.
18. Wirz SE, Overesch G, Kuhnert P, Korczak BM. Genotype and antibiotic resistance analyses of Cam-
pylobacter isolates from ceca and carcasses of slaughtered broiler flocks. Appl Environ Microbiol. 2010;
76(19):6377–86. https://doi.org/10.1128/AEM.00813-10 PMID: 20709846.
19. Kovac J, Cadez N, Stessl B, Stingl K, Gruntar I, Ocepek M, et al. High genetic similarity of ciprofloxacin-
resistant Campylobacter jejuni in central Europe. Frontiers in microbiology. 2015; 6:1169. https://doi.
org/10.3389/fmicb.2015.01169 PMID: 26557112.
20. Strachan NJ, Gormley FJ, Rotariu O, Ogden ID, Miller G, Dunn GM, et al. Attribution of Campylobacter
Infections in Northeast Scotland to Specific Sources by Use of Multilocus Sequence Typing. JInfectDis.
2009; 199(8):1205–8.
21. Koser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown NM, Farrington M, et al. Routine use of
microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog. 2012;
8(8):e1002824. Epub 2012/08/10. https://doi.org/10.1371/journal.ppat.1002824 PMID: 22876174.
22. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, et al. The genome sequence of
the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature. 2000;
403(6770):665–8. https://doi.org/10.1038/35001088 PMID: 10688204
23. Fouts DE, Mongodin EF, Mandrell RE, Miller WG, Rasko DA, Ravel J, et al. Major structural differences
and novel potential virulence mechanisms from the genomes of multiple campylobacter species. PLoS-
Biol. 2005; 3(1):e15.
24. Hepworth PJ, Ashelford KE, Hinds J, Gould KA, Witney AA, Williams NJ, et al. Genomic variations
define divergence of water/wildlife-associated Campylobacter jejuni niche specialists from common
clonal complexes. EnvironMicrobiol. 2011; 13(6):1549–60.
Use of genomics to compare C. jejuni from four human infectious disease study datasets
PLOS ONE | https://doi.org/10.1371/journal.pone.0227535 January 30, 2020 13 / 15
25. Zhao S, Tyson GH, Chen Y, Li C, Mukherjee S, Young S, et al. Whole-Genome Sequencing Analysis
Accurately Predicts Antimicrobial Resistance Phenotypes in Campylobacter spp. Appl Environ Micro-
biol. 2016; 82(2):459–66. https://doi.org/10.1128/AEM.02873-15 PMID: 26519386.
26. McIntyre KM, Bolton FJ, Christley RM, Cleary P, Deja E, Durie AE, et al. Fully-integrated, real-time
detection, diagnosis and control of community diarrhoeal disease clusters and outbreaks—the Integrate
Project. JMIR Research Protocols. 2019; https://doi.org/10.2196/13941 PMID: 31573952
27. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome
assembly algorithm and its applications to single-cell sequencing. Journal of computational biology: a
journal of computational molecular cell biology. 2012; 19(5):455–77. https://doi.org/10.1089/cmb.2012.
0021 PMID: 22506599.
28. Simao FA, Waterhouse RM, Ioannidis P, Kriventseva EV, Zdobnov EM. BUSCO: assessing genome
assembly and annotation completeness with single-copy orthologs. Bioinformatics. 2015; 31(19):3210–
2. https://doi.org/10.1093/bioinformatics/btv351 PMID: 26059717.
29. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, et al. MetaPhlAn2 for enhanced
metagenomic taxonomic profiling. Nat Methods. 2015; 12(10):902–3. https://doi.org/10.1038/nmeth.
3589 PMID: 26418763.
30. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9(4):357–9.
https://doi.org/10.1038/nmeth.1923 PMID: 22388286.
31. Sahl JW, Caporaso JG, Rasko DA, Keim P. The large-scale blast score ratio (LS-BSR) pipeline: a
method to rapidly compare genetic content between bacterial genomes. PeerJ. 2014; 2:e332. https://
doi.org/10.7717/peerj.332 PMID: 24749011.
32. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies.
Bioinformatics. 2014; 30(9):1312–3. https://doi.org/10.1093/bioinformatics/btu033 PMID: 24451623.
33. Letunic I, Bork P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annota-
tion. Bioinformatics. 2007; 23(1):127–8. https://doi.org/10.1093/bioinformatics/btl529 PMID: 17050570.
34. Hyatt D, Chen GL, Locascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal: prokaryotic gene recogni-
tion and translation initiation site identification. BMC bioinformatics. 2010; 11:119. https://doi.org/10.
1186/1471-2105-11-119 PMID: 20211023.
35. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol.
1990; 215(3):403–10. https://doi.org/10.1016/S0022-2836(05)80360-2 PMID: 2231712.
36. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in per-
formance and usability. Molecular biology and evolution. 2013; 30(4):772–80. https://doi.org/10.1093/
molbev/mst010 PMID: 23329690.
37. Lim SK, Moon DC, Chae MH, Kim HJ, Nam HM, Kim SR, et al. Macrolide resistance mechanisms and
virulence factors in erythromycin-resistant Campylobacter species isolated from chicken and swine
feces and carcasses. J Vet Med Sci. 2017; 78(12):1791–5. https://doi.org/10.1292/jvms.16-0307 PMID:
27593510.
38. Wei B, Kang M. Molecular Basis of Macrolide Resistance in Campylobacter Strains Isolated from Poul-
try in South Korea. Biomed Res Int. 2018; 2018:4526576. https://doi.org/10.1155/2018/4526576 PMID:
30069469.
39. Elhadidy M, Miller WG, Arguello H, Alvarez-Ordonez A, Duarte A, Dierick K, et al. Genetic Basis and
Clonal Population Structure of Antibiotic Resistance in Campylobacter jejuni Isolated From Broiler Car-
casses in Belgium. Frontiers in microbiology. 2018; 9:1014. https://doi.org/10.3389/fmicb.2018.01014
PMID: 29867900.
40. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population level.
BMC bioinformatics. 2010; 11:595. https://doi.org/10.1186/1471-2105-11-595 PMID: 21143983.
41. Sproston EL, Wimalarathna HML, Sheppard SK. Trends in fluoroquinolone resistance in Campylobac-
ter. Microb Genom. 2018. https://doi.org/10.1099/mgen.0.000198 PMID: 30024366.
42. Kovac J, Cadez N, Lusicky M, Nielsen EM, Ocepek M, Raspor P, et al. The evidence for clonal spread-
ing of quinolone resistance with a particular clonal complex of Campylobacter jejuni. Epidemiol Infect.
2014; 142(12):2595–603. https://doi.org/10.1017/S0950268813003245 PMID: 24534165.
43. Cha W, Mosci RE, Wengert SL, Venegas Vargas C, Rust SR, Bartlett PC, et al. Comparing the Genetic
Diversity and Antimicrobial Resistance Profiles of Campylobacter jejuni Recovered from Cattle and
Humans. Frontiers in microbiology. 2017; 8:818. https://doi.org/10.3389/fmicb.2017.00818 PMID:
28536568.
44. Cody AJ, McCarthy NM, Wimalarathna HL, Colles FM, Clark L, Bowler ICJW, et al. A longitudinal 6-
year study of the molecular epidemiology of clinical campylobacter isolates in Oxfordshire, United king-
dom. J Clin Microbiol. 2012; 50(10):3193–201. https://doi.org/10.1128/JCM.01086-12 PMID:
22814466.
Use of genomics to compare C. jejuni from four human infectious disease study datasets
PLOS ONE | https://doi.org/10.1371/journal.pone.0227535 January 30, 2020 14 / 15
45. Wimalarathna HM, Richardson JF, Lawson AJ, Elson R, Meldrum R, Little CL, et al. Widespread acqui-
sition of antimicrobial resistance among Campylobacter isolates from UK retail poultry and evidence for
clonal expansion of resistant lineages. BMC Microbiol. 2013; 13(1):160. Epub 2013/07/17. https://doi.
org/10.1186/1471-2180-13-160 PMID: 23855904.
46. Strachan NJ, Rotariu O, MacRae M, Sheppard SK, Smith-Palmer A, Cowden J, et al. Operationalising
factors that explain the emergence of infectious diseases: a case study of the human campylobacterio-
sis epidemic. PLoS One. 2013; 8(11):e79331. https://doi.org/10.1371/journal.pone.0079331 PMID:
24278127.
47. Cody AJ, McCarthy NM, Wimalarathna HL, Colles FM, Clark L, Bowler IC, et al. A longitudinal 6-year
study of the molecular epidemiology of clinical campylobacter isolates in Oxfordshire, United kingdom.
J Clin Microbiol. 2012; 50(10):3193–201. Epub 2012/07/21. https://doi.org/10.1128/JCM.01086-12
PMID: 22814466.
48. VARSS. UK Veterinary Antibiotic Resistance and Sales Surveillance Report. https://www.gov.uk/
government/publications/veterinary-antimicrobial-resistance-and-sales-surveillance-2015. 2015.
49. VARSS. UK Veterinary Antibiotic Resistance and Sales Surveillance Report. https://www.gov.uk/
government/publications/veterinary-antimicrobial-resistance-and-sales-surveillance-2016. 2016.
50. BPC. British Poultry Council: BPC Antibiotic Stewardship Report. https://www.britishpoultry.org.uk/
download/bpc-antibiotic-stewardship-report-2017/. 2017.
51. Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, et al. A fluoroquinolone resistance associated muta-
tion in gyrA Affects DNA supercoiling in Campylobacter jejuni. Front Cell Infect Microbiol. 2012; 2:21.
https://doi.org/10.3389/fcimb.2012.00021 PMID: 22919613.
52. Luo N, Pereira S, Sahin O, Lin J, Huang S, Michel L, et al. Enhanced in vivo fitness of fluoroquinolone-
resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci U S A.
2005; 102(3):541–6. https://doi.org/10.1073/pnas.0408966102 PMID: 15634738.
53. Price LB, Johnson E, Vailes R, Silbergeld E. Fluoroquinolone-resistant Campylobacter isolates from
conventional and antibiotic-free chicken products. Environmental health perspectives. 2005;
113(5):557–60. https://doi.org/10.1289/ehp.7647 PMID: 15866763.
54. Humphrey TJ, Jorgensen F, Frost JA, Wadda H, Domingue G, Elviss NC, et al. Prevalence and sub-
types of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and
after treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005; 49(2):690–8. https://doi.
org/10.1128/AAC.49.2.690-698.2005 PMID: 15673753.
Use of genomics to compare C. jejuni from four human infectious disease study datasets
PLOS ONE | https://doi.org/10.1371/journal.pone.0227535 January 30, 2020 15 / 15
